Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CTI BIOPHARMA CORPCTIC · Entity 111865 | Director · EVP, Chief Business Officer | March 01, 2017 | March 06, 2017 |
| Imago BioSciences, Inc.IMGO · Entity 15490 | Chief Financial Officer | July 15, 2021 | July 15, 2021 |
| Nkarta, Inc.NKTX · Entity 6346 | Chief Financial Officer | July 09, 2020 | July 13, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CTI BIOPHARMA CORP
Report date March 01, 2017 · Filed March 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.33 · Expires 2027-02-28 | Direct | 60,000 |
Reported balance
After 2017-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-01 · Grant · Acquired 60,000 · Balance 60,000 F1: The option is scheduled to vest in six semi-annual installments over the three-year period following the grant date, subject to the reporting person's continued employment or service with the issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is scheduled to vest in six semi-annual installments over the three-year period following the grant date, subject to the reporting person's continued employment or service with the issuer through the applicable vesting date.
Imago BioSciences, Inc.
Report date July 15, 2021 · Filed July 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.20 · Expires 2031-02-04 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-07-15 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F2: Reflects a 8.4-for-1 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. F1: The Option vests with respect to 25% of the shares subject thereto on January 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Option vests with respect to 25% of the shares subject thereto on January 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
F2: Reflects a 8.4-for-1 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.
Nkarta, Inc.
Report date July 09, 2020 · Filed July 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2030-07-08 | Direct | 77,800 |
Reported balance
After 2020-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-09 · Grant · Acquired 77,800 · Balance 77,800 F1: This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following July 9, 2020. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement). |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following July 9, 2020. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2020 Filed Jul 13, 2020 21:56 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 77,800 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019047 · doc4.xml · derivative · entry 1 Plunkett Matthew · CIK 0001557551 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,800 Underlying: Common Stock · 77,800 shares Expires 2030-07-08 F1 · derivative.exercise_date: This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following July 9, 2020. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement). Read SEC document |
| March 01, 2017 Filed Mar 6, 2017 16:59 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0000899243-17-006601 · doc4.xml · derivative · entry 1 Plunkett Matthew · CIK 0001557551 · Director · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-02-28 F1 · derivative.exercise_date: The option is scheduled to vest in six semi-annual installments over the three-year period following the grant date, subject to the reporting person's continued employment or service with the issuer through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.